Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer

Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer.

Om avsnittet

Fler avsnitt

Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Prostate Cancer — The Optimal Use of Hormonal Therapy

AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium